ACUR:OTC-Acura Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 0.30

Change

0.00 (0.00)%

Market Cap

USD 6.49M

Volume

2.70K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-04 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TKPHF Takeda Pharmaceutical Company ..

N/A

USD47.27B 19.40 N/A
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD42.58B 18.67 N/A
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD41.74B 19.42 N/A
ESALF Eisai Co., Ltd

N/A

USD19.37B 30.27 N/A
ESALY Eisai Co., Ltd

N/A

USD18.54B 35.01 N/A
SGIOY Shionogi & Co., Ltd

N/A

USD14.34B 1.93 N/A
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD10.84B 20.18 N/A
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD9.93B 20.29 N/A
TEVJF Teva Pharmaceutical Industries..

N/A

USD9.28B 483.60 N/A
GNHAF Vifor Pharma AG

N/A

USD8.99B 49.99 N/A

ETFs Containing ACUR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.43% 88% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.43% 88% B+ 88% B+
Trailing 12 Months  
Capital Gain 43.20% 94% A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.20% 92% A- 87% B+
Trailing 5 Years  
Capital Gain -93.61% 27% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.61% 27% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -29.86% 5% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.86% 5% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 55.86% 53% F 43% F
Risk Adjusted Return -53.46% 14% F 11% F
Market Capitalization 6.49M 51% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets -19.23% 47% F 28% F
Debt to Equity Ratio -126.56% 91% A- 95% A
Technical Ratios  
Short Ratio 0.73 55% F 56% F
Short Percent 1.20% 43% F 50% F
Beta 1.23 45% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.